ClinicalTrials.Veeva

Menu
S

Sharp HealthCare | Sharp Center for Research

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Gemcitabine
Docetaxel
Prednisone
Sacituzumab
Milvexian
Ompenaclid
Platinum
Enobosarm
PD-0325901
RCHOP

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

7 of 26 total trials
Locations recently updated

A Study Comparing Imetelstat Versus Best Available Therapy for the Treatment of Intermediate-2 or High-risk Myelofibrosis (MF) Who Have Not Responded to Janus Kinase (JAK)-Inhibitor Treatment

The purpose of the study is to evaluate the overall survival of participants treated with imetelstat compared to best available therapy with intermed...

Enrolling
Myelofibrosis
Drug: Imetelstat
Drug: Best Available Therapy (BAT)

The purpose of this study is to evaluate that milvexian is superior to placebo, in addition to standard-of-care, in reducing the risk of major advers...

Enrolling
Acute Coronary Syndrome
Drug: Milvexian
Other: Placebo

This is a multi-center, open-label study to investigate the safety, efficacy and pharmacokinetics of REC-4881 (12 mg PO daily doses) for the treatmen...

Active, not recruiting
Solid Tumor
APC Gene Mutation
Drug: REC-4881

This is a Phase 1 study currently evaluating PO administered ompenaclid in combination with FOLFIRI and bevacizumab in patients with advanced (i.e.,...

Enrolling
Colorectal Carcinoma
KRAS Mutation-Related Tumors
Drug: Bevacizumab
Drug: ompenaclid

A Phase 2 multi-center open-label basket trial of nab-sirolimus for adult and adolescent patients with malignant solid tumors harboring pathogenic in...

Active, not recruiting
Solid Tumor
Malignant Neoplasm
Drug: nab-sirolimus

The study is a prospective, randomized controlled phase III trial, to test the efficacy, safety and neurocognitive outcomes of advanced NSCLC patient...

Active, not recruiting
Brain Metastases From Non-small Cell Lung Cancer (NSCLC)
Other: Best Standard of Care
Device: NovoTTF-200M device

DF1001-001 is a study of a new molecule that targets natural killer (NK) cells and T-cell activation signals to specific receptors on cancer cells. T...

Enrolling
Solid Tumor, Adult
Drug: DF1001
Drug: Sacituzumab Govitecan-hziy

Trial sponsors

C
D
Seagen logo
S
A
C
D
Genentech logo
G
I

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems